pazopanib

News alerts, weekly reports and conference planners

Company:

Generic mfg.

Drug class:

Multi-tyrosine kinase inhibitor

Related drugs:

‹

›

No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	pazopanib Sensitive: A1 - Approval pazopanib Sensitive : A1	pazopanib Sensitive: A1 - Approval pazopanib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	pazopanib Sensitive: A1 - Approval pazopanib Sensitive : A1	pazopanib Sensitive: A1 - Approval pazopanib Sensitive : A1
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2
No biomarker	Uterine Corpus Leiomyosarcoma	No biomarker	Uterine Corpus Leiomyosarcoma	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2
No biomarker	Sarcoma	No biomarker	Sarcoma	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2
No biomarker	Gastrointestinal Stromal Tumor	No biomarker	Gastrointestinal Stromal Tumor	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2
No biomarker	Kidney Cancer	No biomarker	Kidney Cancer	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2
SDHB deletion	Gastrointestinal Stromal Tumor	SDHB deletion	Gastrointestinal Stromal Tumor	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2
No biomarker	Merkel Cell Carcinoma	No biomarker	Merkel Cell Carcinoma	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2
TFE3 fusion	Sarcoma	TFE3 fusion	Sarcoma	pazopanib Sensitive: C2 – Inclusion Criteria pazopanib Sensitive : C2	pazopanib Sensitive: C2 – Inclusion Criteria pazopanib Sensitive : C2
HDAC2 expression	Renal Cell Carcinoma	HDAC2 expression	Renal Cell Carcinoma	pazopanib + CG-781 Sensitive: C3 – Early Trials pazopanib + CG-781 Sensitive : C3	pazopanib + CG-781 Sensitive: C3 – Early Trials pazopanib + CG-781 Sensitive : C3
FLT4 T494A	Neuroendocrine Tumor	FLT4 T494A	Neuroendocrine Tumor	pazopanib Resistant: C3 – Early Trials pazopanib Resistant : C3	pazopanib Resistant: C3 – Early Trials pazopanib Resistant : C3
FLT4 R1324L	Neuroendocrine Tumor	FLT4 R1324L	Neuroendocrine Tumor	pazopanib Resistant: C3 – Early Trials pazopanib Resistant : C3	pazopanib Resistant: C3 – Early Trials pazopanib Resistant : C3
TP53 mutation	Neuroendocrine Tumor	TP53 mutation	Neuroendocrine Tumor	pazopanib Sensitive: C3 – Early Trials pazopanib Sensitive : C3	pazopanib Sensitive: C3 – Early Trials pazopanib Sensitive : C3
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	pazopanib Sensitive: C3 – Early Trials pazopanib Sensitive : C3	pazopanib Sensitive: C3 – Early Trials pazopanib Sensitive : C3
VEGFA elevation	Renal Cell Carcinoma	VEGFA elevation	Renal Cell Carcinoma	pazopanib Resistant: C3 – Early Trials pazopanib Resistant : C3	pazopanib Resistant: C3 – Early Trials pazopanib Resistant : C3
CXCL12 elevation	Renal Cell Carcinoma	CXCL12 elevation	Renal Cell Carcinoma	pazopanib Resistant: C3 – Early Trials pazopanib Resistant : C3	pazopanib Resistant: C3 – Early Trials pazopanib Resistant : C3
SPP1-L	Renal Cell Carcinoma	SPP1-L	Renal Cell Carcinoma	pazopanib Sensitive: C3 – Early Trials pazopanib Sensitive : C3	pazopanib Sensitive: C3 – Early Trials pazopanib Sensitive : C3
HGF-L	Renal Cell Carcinoma	HGF-L	Renal Cell Carcinoma	pazopanib Sensitive: C3 – Early Trials pazopanib Sensitive : C3	pazopanib Sensitive: C3 – Early Trials pazopanib Sensitive : C3
CXCL8-L	Renal Cell Carcinoma	CXCL8-L	Renal Cell Carcinoma	pazopanib Sensitive: C3 – Early Trials pazopanib Sensitive : C3	pazopanib Sensitive: C3 – Early Trials pazopanib Sensitive : C3
IL6-L	Renal Cell Carcinoma	IL6-L	Renal Cell Carcinoma	pazopanib Sensitive: C3 – Early Trials pazopanib Sensitive : C3	pazopanib Sensitive: C3 – Early Trials pazopanib Sensitive : C3
VHL mutation	Clear Cell Renal Cell Carcinoma	VHL mutation	Clear Cell Renal Cell Carcinoma	pazopanib Resistant: C3 – Early Trials pazopanib Resistant : C3	pazopanib Resistant: C3 – Early Trials pazopanib Resistant : C3
VHL promoter methylation	Clear Cell Renal Cell Carcinoma	VHL promoter methylation	Clear Cell Renal Cell Carcinoma	pazopanib Resistant: C3 – Early Trials pazopanib Resistant : C3	pazopanib Resistant: C3 – Early Trials pazopanib Resistant : C3
EPAS1 overexpression	Clear Cell Renal Cell Carcinoma	EPAS1 overexpression	Clear Cell Renal Cell Carcinoma	pazopanib Resistant: C3 – Early Trials pazopanib Resistant : C3	pazopanib Resistant: C3 – Early Trials pazopanib Resistant : C3
HIF1A expression	Clear Cell Renal Cell Carcinoma	HIF1A expression	Clear Cell Renal Cell Carcinoma	pazopanib Resistant: C3 – Early Trials pazopanib Resistant : C3	pazopanib Resistant: C3 – Early Trials pazopanib Resistant : C3
KDR elevation	Skin Cancer	KDR elevation	Skin Cancer	pazopanib Sensitive: C3 – Early Trials pazopanib Sensitive : C3	pazopanib Sensitive: C3 – Early Trials pazopanib Sensitive : C3
PD-L1 expression	Soft Tissue Sarcoma	PD-L1 expression	Soft Tissue Sarcoma	pazopanib Resistant: C3 – Early Trials pazopanib Resistant : C3	pazopanib Resistant: C3 – Early Trials pazopanib Resistant : C3
KDR C482R	Clear Cell Renal Cell Carcinoma	KDR C482R	Clear Cell Renal Cell Carcinoma	crizotinib + pazopanib Sensitive: C3 – Early Trials crizotinib + pazopanib Sensitive : C3	crizotinib + pazopanib Sensitive: C3 – Early Trials crizotinib + pazopanib Sensitive : C3
ALK R1209Q	Colon Cancer	ALK R1209Q	Colon Cancer	crizotinib + pazopanib Sensitive: C3 – Early Trials crizotinib + pazopanib Sensitive : C3	crizotinib + pazopanib Sensitive: C3 – Early Trials crizotinib + pazopanib Sensitive : C3

pazopanib

Associations
(76)

Associations
(76)

pazopanib

Associations(76)

Associations(76)

Associations
(76)

Associations
(76)